CHONDROPLUS has been shown to be both safe and effective, with a history of being tested in more clinical studies than any other single-injection hyaluronic acid knee therapy.  

In the pivotal CHONDROPLUS trial:

• No serious adverse events were deemed to be related to the treatment with CHONDROPLUS.  

• The most frequently reported adverse events were joint pain (8.6%), pain at the injection site (2.3%), and joint swelling (1.7%).  

• CHONDROPLUS is safe for repeated courses of therapy, and repeat administration does not increase the occurrence of adverse events.  

Choose CHONDROPLUS for extended-lasting results:

• It has a total joint residence time of approximately 150 days, based on a half-life of 30 days.

• The reported half-life of 30 days (about 4 weeks) in the knee joint for a single injection regimen is the longest of any HA.